Market Place
Sourcing Support
Merck & Co.`s Keytruda posts $8B in Q1 as Qlex picks up steam
01 May 2026 //
FIRSTWORD PHARMA
Merck Halts TROP ADC Development as Keytruda Clock Ticks
30 Apr 2026 //
BIOSPACE
Merck goes with Google for AI push, strikes $1B enterprise deal
25 Apr 2026 //
PR NEWSWIRE
Merck, Rivals Eye Inhibrx Experimental Drug Tied to Keytruda
25 Apr 2026 //
REUTERS
Merck’s Welireg Triplet Fails Phase 3 in first-line kidney Cancer
22 Apr 2026 //
FIERCE PHARMA
US FDA approves Merck`s pill combo to treat HIV
22 Apr 2026 //
PRESS RELEASE
Bioinvent To Showcase BI-1808 And Keytruda In Ovarian Cancer
21 Apr 2026 //
PHARMIWEB
Merck unveils PD-1xVEGF bispecific data in NSCLC
17 Apr 2026 //
FIERCE BIOTECH
Merck, Zhifei Rework Their China Vaccine Distribution Agreement
07 Apr 2026 //
FIERCE PHARMA
Merck Starts Phase 2b/3 Trial of MK-8748 for Wet AMD
02 Apr 2026 //
PHARMIWEB
EC Approve KEYTRUDA + Paclitaxel ± Bevacizumab for Ovarian Cancer
02 Apr 2026 //
PHARMIWEB
Merck Enlists Antibody Hunter Infinimmune For $838M Biobucks
31 Mar 2026 //
FIERCE BIOTECH
Merck`s cholesterol drug meets main goal in head-to-head trial
31 Mar 2026 //
REUTERS
WINREVAIR Shows Ph2 Proof In PH-HFpEF Patients
29 Mar 2026 //
BUSINESSWIRE
Merck to Acquire Terns Pharmaceuticals
25 Mar 2026 //
PRESS RELEASE
Merck, Pfizer`s Bladder Cancer Drug Combo Redefines Standard
02 Mar 2026 //
BIOSPACE
Keytruda + Welireg Cuts RCC Recurrence 28% VS Placebo
28 Feb 2026 //
BUSINESSWIRE
Merck`s Welireg combos deliver 1-2 punch to kidney cancer
28 Feb 2026 //
FIERCE PHARMA
Padcev-Keytruda Combo Wins in MIBC Amid Evolving Landscape
28 Feb 2026 //
FIERCE PHARMA
Keytruda Combo Improves OS in Platinum-Resistant Ovarian Cancer
27 Feb 2026 //
BUSINESSWIRE
Merck, Working Through Gardasil Demand Woes, Cuts Jobs In NC
27 Feb 2026 //
FIERCE PHARMA
Synthekine, Merck Launch STK-012/Keytruda Trial for NSCLC Cancer
26 Feb 2026 //
BUSINESSWIRE
Gilead, Merck Clear Path for Daily HIV Pills with Late-Stage Data
26 Feb 2026 //
BIOSPACE
Merck Shares Late-Breaking Ph 3 DOR/ISL Data at CROI 2026
25 Feb 2026 //
BUSINESSWIRE
Merck Shows Positive ENFLONSIA Data for High-Risk Infants
19 Feb 2026 //
PHARMIWEB
Merck to Present New Bladder, Kidney Cancer Data at 2026 ASCO
12 Feb 2026 //
BUSINESSWIRE
Keytruda Combo Approved for Platinum-Resistant Ovarian Cancer
12 Feb 2026 //
FDA
Immutep Reaches 50% Enrollment In Global Phase III Trial For 1L
06 Feb 2026 //
GLOBENEWSWIRE
Merck lines up $70B+ in revenue opportunities over next decade
03 Feb 2026 //
FIERCE PHARMA
Pfizer Retains Top Spot In Vaccine Rankings As Sanofi Slides
27 Jan 2026 //
FIERCE PHARMA
Merck Backs Off Revolution After Failing To Agree On Price: WSJ
26 Jan 2026 //
BIOSPACE
CEPI Funds $30M Ebola Vaccine Collab With Merck, SK And Others
22 Jan 2026 //
FIERCE PHARMA
Merck, Moderna Sustain 49% Melanoma Risk Reduction At 5 Years
22 Jan 2026 //
FIERCE BIOTECH
FDA Lifts Hold On Merck, Daiichi`s Lung Cancer ADC Trial
13 Jan 2026 //
BIOSPACE
Merck Confident In Growth Despite Keytruda Exclusivity Loss
13 Jan 2026 //
BIOSPACE
Merck Starts Phase 3 Trial Of Calderasib With Keytruda For NSCLC
11 Jan 2026 //
INDPHARMAPOST
Merck in Talks to Buy Drugmaker Revolution Med for up to $32B
10 Jan 2026 //
FINANCIAL TIMES
Merck Starts Phase 3 Trial of KRAS G12C Drug With Keytruda QLEX
07 Jan 2026 //
PHARMIWEB
Evaxion provides update on MSD collab For Gonorrhea EVX-B2
20 Dec 2025 //
FIERCE BIOTECH
Daiichi-Merck Ph. 3 ADC Program On Pause After Patient Deaths
18 Dec 2025 //
FIERCE BIOTECH
Adagene Reveals FDA Fast Track For Muzastotug In Cancer
16 Dec 2025 //
GLOBENEWSWIRE
FDA Launches Probe Into Safety Of Approved Anti-RSV Antibodies
10 Dec 2025 //
BIOSPACE
Merck`s Keytruda SC Launch In Germany Faces Legal Hurdle
05 Dec 2025 //
FIERCE PHARMA
Merck Unveils Alzheimer`s Data on MK-2214, MK-1167 at CTAD 2025
01 Dec 2025 //
PHARMIWEB
Kelun-Biotech Initiates Phase III Trial For SAC-TMT with Keytruda
24 Nov 2025 //
PR NEWSWIRE
Merck To Present Hematology Pipeline Advancements At ASH 2025
24 Nov 2025 //
BUSINESSWIRE
FDA Approves Combo Therapy For Ineligible Bladder Cancer Patients
23 Nov 2025 //
INDPHARMAPOST
Merck`s WINREVAIR Promising In Phase 2 Study For Pulmonary
21 Nov 2025 //
INDPHARMAPOST
EU Approves Subcutaneous Keytruda for All Adult Indications
19 Nov 2025 //
BUSINESSWIRE
Merck`s HIV Combo Matches Gilead`s Biktarvy In Phase 3 Test
19 Nov 2025 //
BUSINESSWIRE
Merck Boosts Winrevair`s Success In Mid-Stage Hypertension Data
19 Nov 2025 //
BUSINESSWIRE
Merck Boosts Winrevair`s Success In Mid-Stage Hypertension Data
18 Nov 2025 //
BUSINESSWIRE
Solve Therapeutics Secures $120M For Leading ADCs In Solid Tumor
17 Nov 2025 //
BUSINESSWIRE
Merck`s Enlicitide Decanoate Reduces LDL-C In HeFH Adults
09 Nov 2025 //
BUSINESSWIRE
Merck Enlicitide Decanoate Lowers LDL-C In Ph3 CORALreef Trial
08 Nov 2025 //
BUSINESSWIRE
Merck`s Pneumococcal Shot Capvaxive Off To `Very Strong Start`
30 Oct 2025 //
FIERCE PHARMA
EC Approves Keytruda Combo for PD-L1+Resectable Head&Neck Cancer
29 Oct 2025 //
BUSINESSWIRE
Welireg`s RCC Wins Could Pad Merck`s Post-Keytruda Sales
28 Oct 2025 //
FIERCE PHARMA
Merck Nabs updated FDA label for PAH med Winrevair
27 Oct 2025 //
BUSINESSWIRE
FDA Prioritizes KEYTRUDA And KEYTRUDA QLEX Combo with Padcev
23 Oct 2025 //
BUSINESSWIRE
